Payment overview · 2025
General Payments
$215.54
9 reported records · 5 companies
Healthcare provider profile · identity verified
Trena Preston, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · HAZARD, KY · NPI 1033131156
Verified facts
What the public records show
CMS Open Payments records show Trena Preston, APRN received $215.54 in general payments during 2025 across 9 reported records.
Axsome Therapeutics, Inc. accounted for 31.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $68.47 | 31.8% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $55.63 | 25.8% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $51.76 | 24.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.62 | 9.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.06 | 8.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $215.54 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $68.47 | 2 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $55.63 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $51.76 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
120 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 244 | 66 |
| Atorvastatin Calcium | Atorvastatin Calcium | 237 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 227 | 55 |
| Metformin Hcl | Metformin Hcl | 184 | 41 |
| Lisinopril | Lisinopril | 176 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 163 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 161 | 44 |
| Omeprazole | Omeprazole | 156 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 131 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 35 |
| Ozempic | Semaglutide | 120 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 112 | 34 |
| Losartan Potassium | Losartan Potassium | 112 | 31 |
| Potassium Chloride | Potassium Chloride | 99 | 21 |
| Simvastatin | Simvastatin | 99 | 21 |
| Montelukast Sodium | Montelukast Sodium | 97 | 26 |
| Furosemide | Furosemide | 85 | 28 |
| Sertraline Hcl | Sertraline Hcl | 85 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 79 | 21 |
| Gabapentin | Gabapentin | 77 | 16 |
| Glipizide | Glipizide | 73 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 70 | 17 |
| Levetiracetam | Levetiracetam | 69 | 11 |
| Ibuprofen | Ibuprofen | 68 | 24 |
| Buspirone Hcl | Buspirone Hcl | 64 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | suppressed |
| Mounjaro | Tirzepatide | 57 | 12 |
| Allopurinol | Allopurinol | 55 | 11 |
| Atenolol | Atenolol | 54 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 26 |
| Clonidine Hcl | Clonidine Hcl | 52 | 13 |
| Famotidine | Famotidine | 52 | 16 |
| Methylprednisolone | Methylprednisolone | 51 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 18 |
| Trazodone Hcl | Trazodone Hcl | 48 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 41 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Alprazolam | Alprazolam | 42 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 41 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 40 | 13 |
| Meloxicam | Meloxicam | 39 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 35 | 11 |
| Baclofen | Baclofen | 34 | 13 |
| Eliquis | Apixaban | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Carvedilol | Carvedilol | 31 | suppressed |
| Ketoconazole | Ketoconazole | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Lactulose | Lactulose | 28 | 11 |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 18 |
| Prednisone | Prednisone | 26 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 19 |
| Fluconazole | Fluconazole | 23 | 17 |
| Glipizide Er | Glipizide | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Cefdinir | Cefdinir | 22 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 15 |
| Azithromycin | Azithromycin | 21 | 17 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 14 |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 16 |
| Nystatin | Nystatin | 18 | 13 |
| Pregabalin | Pregabalin | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Metaxalone | Metaxalone | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Dofetilide | Dofetilide | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $215.54 · 9 records | Axsome Therapeutics, Inc. | Auvelity, CAPLYTA, Dexcom G6 Transmitter, Prolastin-C Liquid, Wegovy | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error